Coral Martinez
Gerontology · Pueblo, CONPI 1013486299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 33.8% of the total. Reporting peaked in 2023 at $966 and has fallen 81.4% since, to $180 in 2025. Among gerontology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$483
- Gilead$289
- Johnson & Johnson$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$232
- Intercept Pharmaceuticals, Inc.$146
- plus $651 from 18 others
What the payments were for
- Food & beverage$3,02098%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $1,042 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $483 |
| Gilead | 18 | $289 |
| Johnson & Johnson(2 entities) | 10 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $232 |
| Intercept Pharmaceuticals, Inc. | 2 | $146 |
| Smith+Nephew | 6 | $121 |
| Nestle Healthcare Nutrition Inc. | 5 | $83 |
| QOL Medical, LLC | 4 | $80 |
| Organon | 3 | $59 |
| Enterra Medical, Inc. | 1 | $42 |
| Bristol Myers Squibb | 2 | $39 |
| AstraZeneca | 2 | $31 |
| Organogenesis Inc. | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $24 |
| Merck | 1 | $20 |
| Ardelyx, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Mimedx Group, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Solventum Corporation | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$124
How this compares
$3,081 in reported general payments places this provider in the 90th percentile of 85 gerontology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $181,475 |
| LinzessLinaclotide | 94 | $87,770 |
| XifaxanRifaximin | 13 | $24,648 |
| Mesalamine | 28 | $8,219 |
| Omeprazole | 172 | $3,906 |
| Dexlansoprazole DrDexlansoprazole | 15 | $3,364 |
| Pantoprazole Sodium | 226 | $3,132 |
| Ursodiol | 12 | $2,540 |
| Esomeprazole Magnesium | 33 | $2,529 |
| Sucralfate | 35 | $1,201 |
| CholestyramineCholestyramine (With Sugar) | 15 | $1,021 |
| Dicyclomine Hcl | 35 | $925 |
| Famotidine | 42 | $754 |
| Nadolol | 16 | $440 |
| Ondansetron OdtOndansetron | 15 | $395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,042 | $87,77094 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $232 | $24,64813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 85 gerontology providers in Colorado.
Other gerontology in Pueblo
- Kimberly RobertsonColorado Springs$9K
- Melinda McClendonColorado Springs$8K
- Nicole ChiekaColorado Springs$6K
- Ashley ReadLoveland$5K
- Rhiannon SundayColorado Springs$5K
- Kimberly CunninghamAurora$4K
- Andrea DavisGrand Junction$4K
- Molly DavisDenver$3K
- Julie HinchmanLakewood$3K
- Eileen QuillinLoveland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.